Board of Directors
Bernard Kelley, Chairman
Byron Dorgan, MBA
Byron Dorgan brings experience in policy making, government affairs and financial management having represented North Dakota in the U.S. Senate from 1992 to 2011 and in the House of Representatives from 1981 to 1992. He served as assistant Democratic floor leader, chairman of the Democratic Policy Committee and chairman of the Committee on Indian Affairs and also was the senior senator on the Appropriations, Energy and Commerce committees.
Prior to being elected to Congress, Dorgan served as North Dakota’s state tax commissioner from 1969 until 1980. The author of four books on governmental policy, Dorgan earned a bachelor’s from the University of North Dakota and an MBA from the University of Denver.
David V. Smith, MBA
David V. Smith is the chief operating officer of IntegenX, a privately held company focused on rapid DNA identification technology. He was previously executive vice president and CFO of Thoratec Corporation and held various financial management positions with Chiron Corporation, including vice president and CFO. Prior to those positions, he was vice president of finance and CFO of Anergen, Inc., and held various financial management positions with Genentech in the U.S. and Europe. Smith is also a director and chair of the audit committee of OncoGenex Pharmaceuticals Inc. He earned a bachelor’s degree in economics and history at Willamette University and an MBA in finance from Golden Gate University.
Dennis Wolf, MBA
John Nicols, MBA
Pam Cheng, MBA
Patrick Yang, PhD
Before joining the Codexis board, Dr. Patrick Y. Yang served as executive vice president and global head of technical operations for Hoffmann-La Roche where he was responsible for Roche’s pharmaceutical and biotech manufacturing operations, process development, quality, regulatory and supply management functions. Before joining Roche upon its acquisition of Genentech, Yang worked as Genentech’s executive vice president of product operations and was a member of the company’s executive committee. He also held leadership roles at Merck, including vice president of Asia/Pacific manufacturing operations and vice president of supply chain management. Prior to Merck, Yang worked for General Electric in various leadership role in engineering, technology and manufacturing. Most recently, Yang worked as executive vice president of Juno Therapeutics in 2017-2019.
Yang currently serves on the board of directors of PharmaEssentia Corporation, Amyris, Inc., Acepodia, Inc., Taiwania Capital Management, and Sana Biotechnology. Yang earned his bachelor's in engineering from National Chiao Tung University in Taiwan, a master's degree in engineering from the University of Cincinnati, and a PhD in engineering from Ohio State University.
Thomas Baruch, JD
Thomas R. Baruch brings significant knowledge of the biotechnology and clean technology industries to the Codexis board, having served on the boards of companies including Calysta Energy, Inc., FORO Energy, Halotechnics, Inc. and Heliotrope Technologies, among others. Baruch is currently on the board of That Man May See Foundation and is a partner of Formation 8, the founder and managing general partner of Baruch Future Ventures, LLC, and a founder and partner emeritus of CMEA Capital. Before starting CMEA, Baruch was a founder and CEO of Microwave Technology, Inc., a supplier of gallium arsenide integrated circuits, and served as president of the Exxon Materials Division.
Baruch is a member of the board of trustees of Rensselaer Polytechnic Institute, the National Advisory Council on Innovation and Entrepreneurship and the Sierra Club Climate Recovery Cabinet. He holds a bachelor’s degree in engineering from Rensselaer Polytechnic Institute and earned his JD from Capital University.